Rapport Therapeutics (NASDAQ:RAPP) Short Interest Down 15.3% in January

Rapport Therapeutics (NASDAQ:RAPP) saw a large decline in short interest in January. As of January 15th, there was short interest totalling 1,500,000 shares, a decline of 15.3% from the December 31st total of 1,770,000 shares. Currently, 8.6% of the shares of the company are short sold. Based on an average daily volume of 104,700 shares, the days-to-cover ratio is presently 14.3 days.

Rapport Therapeutics Stock Performance

NASDAQ RAPP traded up $0.19 on Monday, hitting $16.60. 141,117 shares of the company’s stock were exchanged, compared to its average volume of 102,548. The firm’s 50-day moving average price is $17.78 and its two-hundred day moving average price is $20.45. Rapport Therapeutics has a fifty-two week low of $12.09 and a fifty-two week high of $29.74.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.07. Research analysts expect that Rapport Therapeutics will post -3.65 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RAPP. Values First Advisors Inc. purchased a new position in Rapport Therapeutics during the third quarter worth $31,000. BNP Paribas Financial Markets acquired a new position in Rapport Therapeutics in the 3rd quarter valued at about $34,000. New York State Common Retirement Fund purchased a new position in Rapport Therapeutics in the 4th quarter valued at about $62,000. JPMorgan Chase & Co. acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth about $83,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Rapport Therapeutics during the third quarter worth about $101,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.